Lingrong Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lingrong Yang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Qiqi Gao
The Second Affiliated Hospital, Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China
2 shared publicationsWenwen Jin
The Second Affiliated Hospital, Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China
2 shared publicationsChizhang Chen
Department of Clinical Medicine, Pingyang County Traditional Chinese Medicine Hospital, Meizhou, Zhejiang, China
1 shared publicationChun-Ting Zhou
1 shared publicationFu Xiong
Department of Pediatric Gastroenterology, Sichuan Provincial Women's and Children's Hospital/Women's and Children's Hospital Affiliated to Chengdu Medical College, Chengdu 610000, China
1 shared publicationGongxia Ling
Department of Pediatrics, The Second School of Medicine, Wenzhou Medical University, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
1 shared publication
Latest Publications
- Open Access
- 7 January 2026
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 52 (1)
Recent advancements in pediatric purulent meningitis: diagnosis and treatment
Purulent meningitis is a common disease of the central nervous system affecting children. It arises from various pathogens transmitted through diverse rout
- 7 January 2026
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 52 (1)
Open AccessRecent advancements in pediatric purulent meningitis: diagnosis and treatment
Purulent meningitis is a common disease of the central nervous system affecting children. It arises from various pathogens transmitted through diverse rout
- 15 March 2025
- Vol. 27 (3) , 315-320
[Clinical and drug sensitivity characteristics of invasive non-typhoidal Salmonella enteritis in children aged 0-6 years in Chengdu, China, 2022-2023].
To investigate the clinical characteristics and drug resistance profile of invasive non-typhoidal Salmonella (NTS) enteritis in children in Chengdu, China, providing a reference for rational drug use and empirical treatment in clinical practice. A retrospective analysis was conducted on the clinical data of 130 children with invasive bacterial enteritis due to NTS identified by fecal bacterial culture and the results of drug sensitivity tests for NTS in Chengdu from January 2022 to December 2023. NTS infections were mainly observed from April to September (113 cases, 86.9%), with a peak in August (36 cases, 27.7%). Children aged 90.0% to piperacillin-tazobactam and nitrofurantoin (nitrofurans). The detection rate of multidrug-resistant strains was 48.5% (63/130), and the clinical efficacy of third-generation cephalosporins used in 38 patients (29.2%) was inconsistent with the results of drug sensitivity tests. The peak of invasive NTS enteritis in children aged 0-6 years occurs in August in the Chengdu area, with a relatively high incidence rate in children aged <36 months. The situation of drug resistance is severe for NTS, and piperacillin-tazobactam may be an effective option for treating multidrug-resistant NTS infections in children, while nitrofuran antibiotics might be used to treat such infections.
- 15 March 2025
- Vol. 27 (3) , 315-320
[Clinical and drug sensitivity characteristics of invasive non-typhoidal Salmonella enteritis in children aged 0-6 years in Chengdu, China, 2022-2023].
To investigate the clinical characteristics and drug resistance profile of invasive non-typhoidal Salmonella (NTS) enteritis in children in Chengdu, China, providing a reference for rational drug use and empirical treatment in clinical practice. A retrospective analysis was conducted on the clinical data of 130 children with invasive bacterial enteritis due to NTS identified by fecal bacterial culture and the results of drug sensitivity tests for NTS in Chengdu from January 2022 to December 2023. NTS infections were mainly observed from April to September (113 cases, 86.9%), with a peak in August (36 cases, 27.7%). Children aged 90.0% to piperacillin-tazobactam and nitrofurantoin (nitrofurans). The detection rate of multidrug-resistant strains was 48.5% (63/130), and the clinical efficacy of third-generation cephalosporins used in 38 patients (29.2%) was inconsistent with the results of drug sensitivity tests. The peak of invasive NTS enteritis in children aged 0-6 years occurs in August in the Chengdu area, with a relatively high incidence rate in children aged <36 months. The situation of drug resistance is severe for NTS, and piperacillin-tazobactam may be an effective option for treating multidrug-resistant NTS infections in children, while nitrofuran antibiotics might be used to treat such infections.
- Open Access
- 24 January 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1280792
Progress of Ginsenoside Rb1 in neurological disorders
Ginseng is frequently used in traditional Chinese medicine to treat neurological disorders. The primary active component of ginseng is ginsenoside, which has been classified into more than 110 types based on their chemical structures. Ginsenoside Rb1 (GsRb1)—a protopanaxadiol saponin and a typical ginseng component—exhibits anti-inflammatory, anti-oxidant, anti-apoptotic, and anti-autophagy properties in the nervous system. Neurological disorders remain a leading cause of death and disability globally. GsRb1 effectively treats neurological disorders. To contribute novel insights to the understanding and treatment of neurological disorders, we present a comprehensive review of the pharmacokinetics, actions, mechanisms, and research development of GsRb1 in neurological disorders.
- 24 January 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1280792
Open AccessProgress of Ginsenoside Rb1 in neurological disorders
Ginseng is frequently used in traditional Chinese medicine to treat neurological disorders. The primary active component of ginseng is ginsenoside, which has been classified into more than 110 types based on their chemical structures. Ginsenoside Rb1 (GsRb1)—a protopanaxadiol saponin and a typical ginseng component—exhibits anti-inflammatory, anti-oxidant, anti-apoptotic, and anti-autophagy properties in the nervous system. Neurological disorders remain a leading cause of death and disability globally. GsRb1 effectively treats neurological disorders. To contribute novel insights to the understanding and treatment of neurological disorders, we present a comprehensive review of the pharmacokinetics, actions, mechanisms, and research development of GsRb1 in neurological disorders.